Topic Editors

Department of Chemistry, Pusan National University, Busan 46241, Republic of Korea
Department of Pharmaceutical Sciences, College of Pharmacy and Health Science, Ajman University, Ajman P.O. Box 346, United Arab Emirates

Challenges and Future Prospects of Antibacterial Therapy, 2nd Edition

Abstract submission deadline
30 September 2026
Manuscript submission deadline
30 November 2026
Viewed by
745

Topic Information

Dear Colleagues,

Antibiotic resistance has become one of the most pressing global health issues. The increase in multidrug-resistant (MDR) pathogens has resulted in higher rates of death and illness due to unsuccessful treatments, placing a significant strain on healthcare systems around the world. A key factor in this crisis is the improper and excessive use of antibiotics—not only in medical settings but also in non-medical fields such as agriculture and food production—which has hastened the development and dissemination of resistance. Although there is an urgent demand, creating new and effective treatments against MDR bacteria remains a challenging and ongoing task. Biofilms are microbial communities that adhere to surfaces and resist antibiotics, contributing to chronic infections. Targeting biofilm formation is vital for combating MDR pathogens and improving treatment outcomes. This topic aims to collect pioneering research and thorough reviews that focus on the latest progress in developing novel, biocompatible antimicrobial agents and strategies aimed at counteracting emerging MDR pathogens and biofilm formation. Areas of interest include, but are not limited to, the design, synthesis, and production of new antimicrobial materials and platforms; their biocompatibility assessment; and the evaluation of their therapeutic uses.

Prof. Dr. Kwang-sun Kim
Dr. Zehra Edis
Topic Editors

Keywords

  • antibiotic resistance
  • synergistic antibiotics
  • nanoantibiotics
  • endolysins/bacteriocins
  • outermembrane vesicles
  • photothermal therapy
  • photodynamic therapy
  • ROS-based antimicrobial therapy
  • antibiofilm agents
  • biocompatibility
  • drug delivery system

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Antibiotics
antibiotics
4.6 8.7 2012 15 Days CHF 2900 Submit
International Journal of Molecular Sciences
ijms
4.9 9.0 2000 20.5 Days CHF 2900 Submit
Microbiology Research
microbiolres
2.2 2.8 2010 20.7 Days CHF 1600 Submit
Pharmaceuticals
pharmaceuticals
4.8 7.7 2004 14 Days CHF 2900 Submit
Pharmaceutics
pharmaceutics
5.5 10.0 2009 14.9 Days CHF 2900 Submit
Nanomaterials
nanomaterials
4.3 9.2 2010 15.4 Days CHF 2400 Submit
Microorganisms
microorganisms
4.2 7.7 2013 15.2 Days CHF 2700 Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

  1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
  2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
  3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
  4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
  5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (1 paper)

Order results
Result details
Journals
Select all
Export citation of selected articles as:
11 pages, 235 KB  
Article
Clinical Outcomes of Piperacillin/Tazobactam Treatment in Outpatient Parenteral Antimicrobial Therapy (OPAT) Programs: Comparison of Two Models of Opat Care
by Santiago J. Lora-Escobar, Laura Herrera-Hidalgo, Nerea Castillo-Fernández, Zaira R. Palacios-Baena, Rafael Luque-Márquez, Arístides De Alarcón, Ana Belén Guisado-Gil, Belén Gutierrez-Gutierrez, María Dolores Navarro-Amuedo, Julia Praena-Segovia, Marta Mejías Trueba, Juan Manuel Carmona-Caballero, José Manuel Sánchez Oliva, María Victoria Gil-Navarro and Luis E. López-Cortés
Pharmaceutics 2025, 17(11), 1429; https://doi.org/10.3390/pharmaceutics17111429 - 4 Nov 2025
Viewed by 188
Abstract
Objectives: Piperacillin/tazobactam (P/T) is a broad-spectrum β-lactam antibiotic frequently used in outpatient parenteral antimicrobial therapy programs (OPAT). We aim to compare the clinical outcomes of P/T treatment in two models of OPAT care in order to maximize the utilization of health resources. [...] Read more.
Objectives: Piperacillin/tazobactam (P/T) is a broad-spectrum β-lactam antibiotic frequently used in outpatient parenteral antimicrobial therapy programs (OPAT). We aim to compare the clinical outcomes of P/T treatment in two models of OPAT care in order to maximize the utilization of health resources. Material and methods: We conducted a prospective observational study with retrospective analysis of a cohort of patients treated with P/T delivered every 24 or 48 h in an OPAT program. The primary outcomes were treatment failure during the OPAT episode and 30 day treatment failure. A bivariate and multivariate logistic regression model was built. A two-sided p < 0.05 was considered statistically significant. Results: Between 2012 and 2022, 247 patients were treated with P/T. Treatment was delivered daily in 176 patients (Group 24) and every two days in 71 patients (Group 48). The rate of treatment failure during OPAT in Group 24 and Group 48 was 12.4% (n = 22) and 5.6% (n = 4), respectively (p = 0.112); and the rate of treatment failure 30 days after OPAT treatment end was 18.2% (n = 32) and 21.1% (n = 15) in Group 24 and Group 48, respectively (p = 0.594). Treatment every 24 or 48 h was not associated with higher treatment failure during OPAT or 30 days after finishing OPAT in either bivariate or multivariate analysis. Conclusions: P/T administration in OPAT programs being replaced every two days is feasible without an increase in treatment failure, relapse, or mortality compared to daily drug replacement. These findings should motivate further research to facilitate the implementation of this novel delivery strategy in OPAT programs. Full article
Back to TopTop